Article Text
Leading article
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye
Statistics from Altmetric.com
Footnotes
-
Contributors The manuscript has been written by both authors. No professional or additional help has been sought or obtained.
-
Competing interests GD: Vertex, Abbott, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pharmasett, Pfizer, Roche/Genentech, Merck, Tibotec, Astek, Achillion, Janssen: Advisory Board; Bristol Myers, Gilead Sciences, Human Genome Sciences, Presidio: Advisory board/Safety Monitoring Board; Zymogenetics: Safety Monitoring Board.
-
Provenance and peer review Commissioned; internally peer reviewed.